Indications for: VARIVAX
Varicella (chickenpox) vaccination.
Give by SC or IM inj. ≥13yrs: 1 dose of 0.5mL at elected date and a 2nd dose of 0.5mL at least 4 weeks later.
<12mos: not established. Give by SC or IM inj. 12mos–12yrs: administer 1st dose of 0.5mL at 12 to 15 months of age but may give anytime through 12yrs of age, then give 2nd dose at 4–6yrs of age.
Hypersensitivity to gelatin or neomycin. Immunodeficient or immunosuppressed. Active febrile illness with fever >101.3⁰F (>38.5⁰C). Active untreated tuberculosis. During pregnancy or individuals who are planning on becoming pregnant in the next 3 months.
Have epinephrine inj (1:1000) available. Defer vaccination if family history of congenital or hereditary immunodeficiency until immunocompetent. Avoid contact with susceptible high-risk individuals for up to 6 weeks after vaccination. HIV-infected: refer to ACIP recommendations. Nursing mothers.
Avoid salicylates in patients (12 months through 17 years of age) for 6 weeks after vaccination. Concomitant administration with immune globulins and other blood products may interfere with the expected immune response; refer to ACIP recommendations. May interfere with tuberculin skin test. Separate by at least 1 month between a dose of a live attenuated measles virus-containing vaccine and Varivax. In children through 12yrs, separate by at least 3 months between 2 doses of a live attenuated varicella virus-containing vaccine and Varivax.
Fever, inj site reactions, rash; others.
Generic Drug Availability:
Single-dose vials—10 (w. diluent)